Abbott Laboratories $ABT Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board raised its position in Abbott Laboratories (NYSE:ABT) by 34.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,316,034 shares of the healthcare product maker’s stock after acquiring an additional 338,256 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.08% of Abbott Laboratories worth $176,270,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. IMG Wealth Management Inc. grew its holdings in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares in the last quarter. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc purchased a new stake in shares of Abbott Laboratories during the third quarter worth $31,000. Anfield Capital Management LLC raised its stake in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories in the second quarter valued at $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of several recent research reports. Citigroup cut their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. BTIG Research cut their target price on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Daiwa Securities Group dropped their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, Sanford C. Bernstein decreased their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Insider Activity

In other news, Director Daniel J. Starks purchased 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director directly owned 6,738,817 shares of the company’s stock, valued at $732,711,572.41. This represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Down 1.8%

ABT stock opened at $111.52 on Friday. The stock has a market cap of $193.91 billion, a P/E ratio of 29.98, a PEG ratio of 1.81 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The company’s 50 day moving average is $119.73 and its two-hundred day moving average is $126.51.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same period last year, the firm posted $1.34 EPS. The company’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.